Widely used:Recently Viewed
Clear AllQuality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$233 Mln
Revenue (TTM)
$31 Mln
Net Profit (TTM)
$0 Mln
ROE
-10.1 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
57.9
Industry P/E
--
EV/EBITDA
20.3
Div. Yield
0 %
Debt to Equity
7.8
Book Value
$--
EPS
$-0.5
Face value
--
Shares outstanding
27,618,700
CFO
$-91.54 Mln
EBITDA
$-110.71 Mln
Net Profit
$-111.57 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Fennec Pharmaceuticals (FENC)
| 31.6 | 39.8 | 30.0 | 14.8 | 14.6 | 1.6 | 13.9 |
|
BSE Sensex
| 4.4 | 2.8 | 10.2 | 6.8 | 14.6 | 19.5 | 12.0 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|---|
|
Fennec Pharmaceuticals (FENC)
| 16.9 | 118.2 | -40.9 | 14.8 | 1.7 | -36.2 | 368.6 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Fennec Pharmaceuticals (FENC)
|
8.3 | 232.8 | 30.9 | -14.1 | -32.8 | -- | -- | 57.9 |
| 3.2 | 964.1 | 23.1 | -167.9 | -1,294.8 | -16 | -- | 0.9 | |
| 8.2 | 1,093.0 | 247.3 | 39.9 | 7.2 | 10.8 | 30 | 3.1 | |
| 3.9 | 176.7 | 0.0 | -27.0 | -- | -65.9 | -- | 5.2 | |
| 2.0 | 13.8 | 0.0 | -5.8 | -- | -66.6 | -- | 2.2 | |
| 1.7 | 75.9 | 0.0 | -28.5 | -- | -23.7 | -- | 0.7 | |
| 2.7 | 3.4 | 2,375.8 | -6,375.8 | -177.6 | -181.4 | -- | 0.5 | |
| 1.7 | 93.6 | 0.0 | -51.9 | -- | -- | -- | 5.0 | |
| 32.8 | 2,467.8 | 7.5 | -251.5 | -2,936.8 | -33.5 | -- | 3.4 | |
| 0.1 | 95.4 | 27.5 | -101.6 | -167.9 | -60.6 | -- | 0.3 |
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in... pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina. Address: 68 TW Alexander Drive, Research Triangle Park, NC, United States, 27709 Read more
CEO & Director
Mr. Rostislav Raykov
CEO & Director
Mr. Rostislav Raykov
Headquarters
Research Triangle Park, NC
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Fennec Pharmaceuticals Inc (FENC) stood at $ 55 Mln as on 31-Mar-25
The share price of Fennec Pharmaceuticals Inc (FENC) is $8.32 (NASDAQ) as of 12-Jun-2025 16:01 EDT. Fennec Pharmaceuticals Inc (FENC) has given a return of 14.59% in the last 3 years.
Fennec Pharmaceuticals Inc (FENC) has a market capitalisation of $ 233 Mln as on 11-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Fennec Pharmaceuticals Inc (FENC) is 57.93 times as on 11-Jun-2025, a 1589% premium to its peers’ median range of 3.43 times.
Since, TTM earnings of Fennec Pharmaceuticals Inc (FENC) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Fennec Pharmaceuticals Inc (FENC) and enter the required number of quantities and click on buy to purchase the shares of Fennec Pharmaceuticals Inc (FENC).
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina. Address: 68 TW Alexander Drive, Research Triangle Park, NC, United States, 27709
The CEO & director of Mr. Rostislav Raykov. is Fennec Pharmaceuticals Inc (FENC), and CFO & Sr. VP is Mr. Rostislav Raykov.
There is no promoter pledging in Fennec Pharmaceuticals Inc (FENC).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
328
|
|
|
145
|
|
|
86
|
|
|
23
|
|
|
15
|
|
|
10
|
|
|
7
|
|
|
1
|
|
|
0
|
| Fennec Pharmaceuticals Inc. (FENC) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
-32.85
|
|
Net Margin(%)
|
-45.52
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Fennec Pharmaceuticals Inc (FENC) was $0 Mln.
$0.12
(
